Evommune Announces Pricing of its Initial Public Offering
PALO ALTO, Calif., Nov. 5, 2025 /PRNewswire/ — Evommune, Inc. (“Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the pricing of its initial public offering of 9,375,000 shares of common…